StockData
enGene Therapeutics Inc. logo

enGene Therapeutics Inc. (ENGN) company profile

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)

Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%

About enGene Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

enGene Holdings Inc. is a clinical-stage biotechnology company developing targeted genetic medicines delivered to mucosal tissues. Utilizing its proprietary DDX non-viral gene delivery platform, the company focuses on creating therapies for localized, high-unmet-need diseases. Its primary product candidate is detalimogene voraplasmid, an investigational treatment being evaluated in clinical trials for non-muscle invasive bladder cancer, specifically targeting patients with Bacillus Calmette-Guérin-unresponsive disease. The organization manages its research and development operations as a single business segment directed at treating bladder cancer patients.

The company conducts its operations across Canada and the United States, utilizing corporate and laboratory facilities to advance its clinical pipeline. enGene maintains its principal executive offices in Saint-Laurent, Quebec, Canada.

Summary of the business section of enGene Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
enGene Therapeutics Inc.
Headquarters
Saint-Laurent, Quebec, Canada
Address
4868 Rue Levy, Suite 220
Phone
(514) 332-4888
Website
engene.com
Employees
82, Oct 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Z4
Fiscal year ends
October 31
Auditor
KPMG LLP, Montreal, Canada

Stock & identifiers

Ticker
ENGN
Other tickers
ENGNW
Exchange
Nasdaq
IPO date
Feb 1, 2022
Shares outstanding
67M, Sep 2, 2026
Public float
$154.18M, Apr 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1980845
CUSIP
29286X101
ISIN
CA29286X1015
FIGI
BBG01J1GCYW7
Share class FIGI
BBG01J1GCYX6
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William GrossmanInterim Chief Medical Officer, Director5,102
Ronald Harold Wilfred CooperCEO & President, Director10,000
Jason DuncanChief Legal & Admin Officer0
Constantine ChinoporosInterim Chief Business Officer–
Kathleen P. RichtonSVP, Finance and Treasurer6,900
Anthony Tzeyew CheungChief Scientific Officer102,873
Jill BuckChief Development Officer–
Alexander Julian NicholsChief Strategy & Ops. Ofc–
D. Ryan DawsChief Financial Officer–
Lee GiguereChief Legal Ofc. and Corp Secy–
Joan ConnollyChief Technology Officer–
Matthew Ross BoydChief Regulatory Officer7,500
Hussein SweitiChief Medical Officer–
Amy PottChief Global Comm. Ofc.–
Raj Som PruthiChief Medical Officer–
Paul J. HastingsDirector–
Lota S. ZothDirector–
Wouter JoustraDirector–
Gerald A. BrunkDirector238,851
Philip Astley-SparkeDirector20,000
Richard M. GlickmanDirector24,675
Michael Thomas HeffernanDirector–
Jasper BosDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Ronald H.W. Cooper
Chief Executive Officer and President
$700.00K–$4.54M$483.00K$30.53K$5.76M-32%
Ryan Daws
Chief Financial Officer
$473.00K–$1.50M$222.64K$23.39K$2.22M–
Hussein Sweiti
Chief Medical Officer
$43.75K$212.20K$2.89M–$1.62K$3.15M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of October 31, 2025, we had 82 employees, including 81 full-time employees, 51 of whom were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 9, 2026Name changeName changed from enGene Holdings Inc. to enGene Therapeutics Inc.
Oct 31, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 31, 2023ListingRegistration of securities on an exchange (Form 8-A)
Aug 9, 2023MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?